SG11201607938UA - Methods for diagnosing and treating inflammatory bowel disease - Google Patents

Methods for diagnosing and treating inflammatory bowel disease

Info

Publication number
SG11201607938UA
SG11201607938UA SG11201607938UA SG11201607938UA SG11201607938UA SG 11201607938U A SG11201607938U A SG 11201607938UA SG 11201607938U A SG11201607938U A SG 11201607938UA SG 11201607938U A SG11201607938U A SG 11201607938UA SG 11201607938U A SG11201607938U A SG 11201607938UA
Authority
SG
Singapore
Prior art keywords
diagnosing
methods
inflammatory bowel
bowel disease
treating inflammatory
Prior art date
Application number
SG11201607938UA
Inventor
Jason A Hackney
Mary Keir
Gaik Wei Tew
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201607938UA publication Critical patent/SG11201607938UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201607938UA 2014-03-27 2015-03-26 Methods for diagnosing and treating inflammatory bowel disease SG11201607938UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461971379P 2014-03-27 2014-03-27
PCT/US2015/022762 WO2015148809A1 (en) 2014-03-27 2015-03-26 Methods for diagnosing and treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
SG11201607938UA true SG11201607938UA (en) 2016-10-28

Family

ID=54196399

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607938UA SG11201607938UA (en) 2014-03-27 2015-03-26 Methods for diagnosing and treating inflammatory bowel disease

Country Status (15)

Country Link
US (4) US10273542B2 (en)
EP (1) EP3122377A4 (en)
JP (3) JP7054990B2 (en)
KR (2) KR102397324B1 (en)
CN (2) CN113604543A (en)
AR (1) AR099856A1 (en)
AU (3) AU2015235986B2 (en)
BR (1) BR112016020053A2 (en)
CA (1) CA2939246A1 (en)
IL (2) IL247266B (en)
MA (1) MA39804A (en)
MX (2) MX2016012282A (en)
RU (1) RU2016136716A (en)
SG (1) SG11201607938UA (en)
WO (1) WO2015148809A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101361905B1 (en) * 2008-05-16 2014-02-21 제넨테크, 인크. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
CA2939246A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CA2972099A1 (en) * 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
CN107083423B (en) * 2017-03-27 2022-01-28 北京极客基因科技有限公司 Drug target prediction and drug full-range evaluation method
WO2019200202A1 (en) 2018-04-12 2019-10-17 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
US20220364171A1 (en) * 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
JP2022523564A (en) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド Data compression and communication using machine learning
KR20220102669A (en) 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 Inhibition of human integrin α4β7
JP2023536158A (en) 2020-07-31 2023-08-23 ジェネンテック， インコーポレイテッド Anti-integrin β7 antibody formulation and device
WO2023061502A1 (en) * 2021-10-15 2023-04-20 苏州生物医药转化工程中心 Bispecific binding molecule
CN114085908B (en) * 2021-10-30 2023-08-08 中国人民解放军陆军军医大学第一附属医院 Gene target combination for evaluating glioblastoma treatment effect and application thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4256833A (en) 1979-01-08 1981-03-17 Majid Ali Enzyme immunoassay for allergic disorders
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A (en) 1988-04-28 1989-10-29 Univ Leland Stanford Junior RESEPTORDETERMINANTER I ANTI-T-CELLER FOER BEHANDLING AV AUTOIMMUNSJUKDOM.
ATE135397T1 (en) 1988-09-23 1996-03-15 Cetus Oncology Corp CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
ES2062519T5 (en) 1989-03-21 2003-07-16 Immune Response Corp Inc VACCINATION AND METHODS AGAINST DISEASES ORIGINATED FROM PATHOGENIC RESPONSES THROUGH SPECIFIC POPULATIONS OF LYMPHOCYTES T.
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
DE69031919T3 (en) 1989-07-19 2005-01-27 Connetics Corp., Palo Alto T-CELL RECEPTOR PEPTIDES AS A CLEANER FOR AUTOIMMUNE AND BAD DISEASES
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
DE69333807T2 (en) 1992-02-06 2006-02-02 Chiron Corp., Emeryville MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
PL209786B1 (en) 1999-01-15 2011-10-31 Genentech Inc Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant
MXPA02010507A (en) 2000-04-25 2003-05-14 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas.
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005009339A2 (en) * 2003-05-30 2005-02-03 Pathway Diagnostics Corporation, Inc. (a Delaware Corporation) Inflammatory bowel diseases
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
KR101364276B1 (en) 2004-09-03 2014-02-20 제넨테크, 인크. Humanized anti-beta7 antagonists and uses therefor
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
JP2009519017A (en) * 2005-12-07 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment and diagnosis of inflammatory diseases
BRPI0713000A8 (en) * 2006-06-12 2017-12-05 Trubion Pharmaceuticals Inc SINGLE CHAIN MULTIESPECIFIC BINDING PROTEIN, PHARMACEUTICAL COMPOSITION AND USE OF SAID SINGLE CHAIN MULTIESPECIFIC BINDING PROTEIN
WO2008028031A2 (en) * 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel
CA2675583A1 (en) * 2007-01-16 2008-07-24 Wyeth Inflammation treatment, detection and monitoring via trem-1
CN103933573A (en) * 2007-02-28 2014-07-23 默沙东公司 Combination therapy for treatment of immune disorders
TW200848431A (en) * 2007-06-12 2008-12-16 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
US9068230B2 (en) * 2007-11-07 2015-06-30 Genentech, Inc. Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
HUE026542T2 (en) * 2008-02-19 2016-06-28 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
US20110117111A1 (en) * 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
KR101361905B1 (en) * 2008-05-16 2014-02-21 제넨테크, 인크. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP2347256A4 (en) * 2008-10-09 2012-02-08 Alfagene Bioscience Inc Use and identification of biomarkers for gastrointestinal diseases
EP2352762A1 (en) * 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
NZ619527A (en) * 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
CA2768711A1 (en) * 2009-07-20 2011-01-27 Genentech, Inc. Gene expression markers for crohn's disease
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US8766034B2 (en) * 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
EP2668287B1 (en) * 2011-01-25 2017-09-06 TC LAND Expression Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from rheumatoid arthritis to tnf-alpha blocking monoclonal antibody
WO2012135589A1 (en) * 2011-03-31 2012-10-04 Genentech, Inc. Methods of administering beta7 integrin antagonists
US20130040835A1 (en) * 2011-05-05 2013-02-14 Exagen Diagnostics, Inc Genes predictive of anti-TNF response in inflammatory diseases
CN102876793B (en) * 2012-09-29 2014-03-12 山东省皮肤病性病防治研究所 Application of single nucleotide polymorphism rs2058660 to detecting susceptibility gene of leprosy
CN102876794B (en) * 2012-09-29 2014-07-02 山东省皮肤病性病防治研究所 Application of mononucleotide polymorphic rs6871626 in detection of susceptibility genes of lepriasis
WO2014055824A1 (en) 2012-10-05 2014-04-10 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CN105143876B (en) 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 Biomarker is used to assess the purposes with 7 integrin antagonists of β treatment gastrointestinal inflammatory illness
CA2939246A1 (en) * 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease

Also Published As

Publication number Publication date
US20220186314A1 (en) 2022-06-16
JP2020062013A (en) 2020-04-23
AR099856A1 (en) 2016-08-24
US20170233809A1 (en) 2017-08-17
RU2016136716A (en) 2018-04-28
AU2021200518B2 (en) 2021-03-04
JP2017511131A (en) 2017-04-20
EP3122377A4 (en) 2018-03-14
WO2015148809A1 (en) 2015-10-01
KR20220065091A (en) 2022-05-19
KR20160130780A (en) 2016-11-14
AU2021203296A1 (en) 2021-06-17
KR102397324B1 (en) 2022-05-13
AU2015235986A1 (en) 2016-08-25
IL247266B (en) 2020-08-31
US20200325538A1 (en) 2020-10-15
CN113604543A (en) 2021-11-05
CN106102767A (en) 2016-11-09
AU2021200518A1 (en) 2021-02-25
AU2015235986B2 (en) 2020-12-03
MX2022010809A (en) 2022-09-27
CA2939246A1 (en) 2015-10-01
US20190256913A1 (en) 2019-08-22
US11261493B2 (en) 2022-03-01
BR112016020053A2 (en) 2018-02-20
EP3122377A1 (en) 2017-02-01
JP2022043033A (en) 2022-03-15
MA39804A (en) 2017-02-01
US10273542B2 (en) 2019-04-30
MX2016012282A (en) 2017-01-06
IL247266A0 (en) 2016-09-29
JP7054990B2 (en) 2022-04-15
CN106102767B (en) 2021-08-10
US10669587B2 (en) 2020-06-02
IL276516A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
IL276516A (en) Methods for diagnosing and treating inflammatory bowel disease
HK1232141A1 (en) Methods and compositions for treating huntingtons disease
HK1219512A1 (en) Methods for diagnosing and treating inflammatory bowel disease
HK1243141A1 (en) Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
EP2971127A4 (en) Methods for the diagnosis and treatment of inflammatory bowel disease
IL247540A0 (en) Endoscopic measurement system and method
AP2016009549A0 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
IL269529A (en) Methods for diagnosing and treating inflammatory bowel disease
HUE055913T2 (en) Methods and compositions for diagnosis and treatment of glioblastoma
SG11201605105UA (en) Disease detection system and disease detection method
IL261738A (en) Method and composition for treating inflammatory bowel disease
GB201417165D0 (en) Treatments for Autoimmune Disease
IL249098A0 (en) Methods and compositions for treating allergy and inflammatory diseases
GB201413357D0 (en) Antibodies for treatment and diagnosis
PT3164394T (en) Gls1 inhibitors for treating disease
PT3210018T (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
GB201721287D0 (en) Treatment for inflammatory disease
SG10201404895XA (en) Diagnosis
EP3602041A4 (en) Methods for diagnosing and treating inflammatory bowel disease
IL252904A0 (en) Methods and agents for treating disease
SG11201609522TA (en) Methods for treating cardiovascular diseases
GB201409851D0 (en) Diagnostic method
IL250402A0 (en) Method for detecting sickle-cell disease and kit for implementing same
HK1218249A1 (en) Compounds and methods for treating inflammatory bowel diseases
GB201700439D0 (en) Methods for assessing vaginal atrophy